Evolution of phage display libraries for therapeutic antibody discovery
- PMID: 37222232
- PMCID: PMC10210849
- DOI: 10.1080/19420862.2023.2213793
Evolution of phage display libraries for therapeutic antibody discovery
Abstract
Monoclonal antibodies (mAbs) and their derivatives have emerged as one of the most important classes of biotherapeutics in recent decades. The success of mAb is due to their high versatility, high target specificity, excellent clinical safety profile, and efficacy. Antibody discovery, the most upstream stage of the antibody development pipeline, plays a pivotal role in determination of the clinical outcome of an mAb product. Phage display technology, originally developed for peptide directed evolution, has been extensively applied to discovery of fully human antibodies due to its unprecedented advantages. The value of phage display technology has been proven by a number of approved mAbs, including several top-selling mAb drugs, derived from the technology. Since antibody phage display was first established over 30 years ago, phage display platforms have been developed to generate mAbs targeting difficult-to-target antigens and tackle the drawbacks present in in vivo antibody discovery approaches. More recently, the new generation of phage display libraries have been optimized for discovery of mAbs with "drug-like" properties. This review will summarize the principles of antibody phage display and design of three generations of antibody phage display libraries.
Keywords: Antibody developability; antibody selection; library design; phage display; therapeutic antibody discovery.
Conflict of interest statement
No potential conflict of interest was reported by the author.
Figures

Similar articles
-
Phage Display Derived Monoclonal Antibodies: From Bench to Bedside.Front Immunol. 2020 Aug 28;11:1986. doi: 10.3389/fimmu.2020.01986. eCollection 2020. Front Immunol. 2020. PMID: 32983137 Free PMC article. Review.
-
Phage antibody display libraries: a powerful antibody discovery platform for immunotherapy.Crit Rev Biotechnol. 2016;36(2):276-89. doi: 10.3109/07388551.2014.958978. Epub 2014 Nov 14. Crit Rev Biotechnol. 2016. PMID: 25394539 Review.
-
Phage display antibody libraries: A robust approach for generation of recombinant human monoclonal antibodies.Int J Biol Macromol. 2019 Aug 15;135:907-918. doi: 10.1016/j.ijbiomac.2019.06.006. Epub 2019 Jun 3. Int J Biol Macromol. 2019. PMID: 31170490 Review.
-
Phage display-derived human antibodies in clinical development and therapy.MAbs. 2016 Oct;8(7):1177-1194. doi: 10.1080/19420862.2016.1212149. Epub 2016 Jul 14. MAbs. 2016. PMID: 27416017 Free PMC article. Review.
-
In vivo Phage Display: A promising selection strategy for the improvement of antibody targeting and drug delivery properties.Front Microbiol. 2022 Sep 26;13:962124. doi: 10.3389/fmicb.2022.962124. eCollection 2022. Front Microbiol. 2022. PMID: 36225354 Free PMC article. Review.
Cited by
-
Engineering and Bio/Nanotechnological Applications of Virus Particles.Subcell Biochem. 2024;105:823-878. doi: 10.1007/978-3-031-65187-8_22. Subcell Biochem. 2024. PMID: 39738964 Review.
-
Discovery of Therapeutic Antibodies Targeting Complex Multi-Spanning Membrane Proteins.BioDrugs. 2024 Nov;38(6):769-794. doi: 10.1007/s40259-024-00682-1. Epub 2024 Oct 25. BioDrugs. 2024. PMID: 39453540 Free PMC article. Review.
-
Discovery of Antibodies Against Endemic Coronaviruses with NGS-Based Human Fab Phage Display Platform.Antibodies (Basel). 2025 Mar 27;14(2):28. doi: 10.3390/antib14020028. Antibodies (Basel). 2025. PMID: 40265409 Free PMC article.
-
Phage Display in Cancer Research: Special Issue Editorial.Viruses. 2024 Jun 17;16(6):968. doi: 10.3390/v16060968. Viruses. 2024. PMID: 38932260 Free PMC article.
-
A next-generation Fab library platform directly yielding drug-like antibodies with high affinity, diversity, and developability.MAbs. 2024 Jan-Dec;16(1):2394230. doi: 10.1080/19420862.2024.2394230. Epub 2024 Aug 27. MAbs. 2024. PMID: 39192463 Free PMC article.
References
-
- Roth KDR, Wenzel EV, Ruschig M, Steinke S, Langreder N, Heine PA, Schneider KT, Ballmann R, Fuhner V, Kuhn P, et al. Developing recombinant antibodies by phage display against infectious diseases and toxins for diagnostics and therapy. Front Cell Infect Microbiol. 2021;11:697876. PMID: 34307196. doi:10.3389/fcimb.2021.697876. - DOI - PMC - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources